Document is current
Any future updates will be listed below
-
Authors
Grabski, Isabella N.
Schneider, Jaime L.
Hanahan, Sara
Ravi, Arvind
Gainor, Justin F.
Haigis, Kevin M.
Irizarry, Rafael A.
Haigis, Marcia C.
- License Information
-
More Information
Article History
Received: 16 October 2025
Accepted: 21 April 2026
First Online: 12 May 2026
Competing interests
: J.L.S. has received honoraria from the Academy of Continued Healthcare Learning, Springer Healthcare, Targeted Oncology, Total Health Conferencing, DAVA Oncology, and Physicians’ Education Resource; travel support from DAVA Oncology; and research funding from Gilead. A.R. consults for Halo LLC and has received research support from IBM to their institution. J.F.G. has served as a compensated consultant for Amgen, AstraZeneca, Mariana Therapeutics, Mirati Therapeutics, Merus Pharmaceuticals, Nuvalent, Pfizer, Novocure, AI Proteins, Novartis, Silverback Therapeutics, Sanofi, Blueprint Medicines, Bristol Myers Squibb, Genentech, Gilead Sciences, Revolution Medicines, Janssen, ITeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Lilly/Loxo, Merck, Moderna Therapeutics, and Takeda; has received honoraria from Novartis, Merck, Pfizer, and Takeda; has received institutional research funding from Adaptimmune, Alexo Therapeutics, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Jounce Therapeutics, Merck, Moderna Therapeutics, Novartis, NextPoint Therapeutics, and Palleon Pharmaceuticals; has received additional research support from Novartis, Genentech, and Takeda; holds equity in AI Proteins; and has an immediate family member who holds equity in and is employed by Ironwood Pharmaceuticals. M.C.H. serves on the scientific advisory boards of MitoQ, Alixia Therapeutics, Samyang Roundsquare, and Minovia, and is a scientific founder and member of the scientific advisory board for Refuel Bio. M.C.H. receives unrelated research funding from Refuel Bio. The other authors declare no competing financial or non-financial interests.
